Phio Pharmaceuticals Corp. (PHIO) · Nov 5, 2026 · Earnings
In line — Implied EPS roughly -$0.35 vs ~$0.36 consensus
Phio’s third-quarter earnings were roughly in line, while PH-762 cleared manufacturing and FDA-submission milestones ahead of a planned Phase 2b trial.
Phio is a cash-burning, single-program biotech centered on moving PH-762 from its completed Phase 1b skin-cancer study into a planned Phase 2b trial in early 2027. The quarter is therefore less about commercial performance than whether the company is executing the regulatory, manufacturing, and funding steps needed to reach that trial.
The operational milestones are on track, but mostly confirm the existing plan. Phio completed commercial-scale drug-substance manufacturing, shipped material for drug-product production, and submitted its final Phase 1b report and proposed Phase 2b strategy to the FDA. 〔0〕 These were already telegraphed in prior updates, so the filing advances execution more than it changes the story.
The next meaningful value point is now FDA feedback, not the earnings line. The company expects a response by the end of November 2026 on the proposed development strategy and next steps. 〔1〕 That response will determine whether the planned first-quarter 2027 Phase 2b start remains intact or needs redesign.
The financial results were broadly in line, but the cost of advancing the program is rising quickly. The implied quarterly loss is close to the published consensus of roughly $0.36 per share, while research spending jumped 159% as toxicology, drug-substance, and clinical-supply work moved forward. Cash fell to $10.6 million from $21.0 million at year-end, leaving less room for execution slippage or unexpected regulatory costs.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Cash and equivalents (Balance Sheet) | $10.6M | ||
| R&D expense (Expense discussion) | $3.0M (+159%) | $1.1M | |
| Net loss (Expense discussion) | $4.2M | $2.4M | |
| Implied EPS (calculated) | ~-$0.35 | ~-$0.36 |
Bottom line: Phio is executing the known PH-762 development plan, with the FDA response now the real test. The quarter is roughly in line financially and modestly constructive operationally, but cash burn makes the path less forgiving than the milestone headlines suggest.
FDA response on PH-762 development strategy, by end-November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!